GNMSF News and Press, Genmab A/S Dkk From 12/21/23

2023-12-21 13:05:16 ET Summary Valuations in the biotech market have fallen, making it a good time for acquisitions in the industry. Investors should focus on commercial-stage biotech companies that generate revenue, as they provide a safety net in uncertain economic conditions. ...

2023-12-14 12:25:24 ET Summary Biopharmaceutical sector valuations have become more attractive after a significant decline in 2021. Larger drug companies are making acquisitions and partnerships with small-cap stocks at generous premiums. Money managers are under-invested in t...

Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...

2023-11-07 14:32:09 ET Genmab A/S (GMAB) Q3 2023 Earnings Conference Call November 07, 2023 12:00 PM ET Company Participants Jan van de Winkel - Co-Founder, President & Chief Executive Officer Anthony Pagano - Executive Vice President & Chief Financial Office...

November 7, 2023 Copenhagen, Denmark; Interim Report for the First Nine Months Ended September 30, 2023 Highlights Epcoritamab (TEPKINLY ® ) was granted conditional marketing authorization by the European Commission (EC) to treat adults with relapsed or re...

Company Announcement Net sales of DARZALEX ® in the third quarter of 2023 totaled USD 2,499 million Genmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN, Denmark; October 17, 2023 – Genmab A/S ...

Company Announcement TEPKINLY ® (epcoritamab) is the first and only subcutaneous bispecific antibody approved as a monotherapy for adult patients with relapsed or refractory ( R/R ) d iffuse large B-cell lymphoma ( DLBCL )...

Company Announcement Phase 3 innovaTV 301 confirmatory trial met its primary endpoint of improved overall survival ( OS) at prede termined , independent interim analysis T rial results to be submitted for presentation at a future medical ...

2023-08-03 17:58:02 ET Genmab A/S (GMAB) Q2 2023 Earnings Conference Call August 3, 2023 12:00 PM ET Company Participants Jan van de Winkel - Co-Founder, President & CEO Anthony Pagano - EVP & CFO Judith Klimovsky - Chief Development Officer Anthony M...

August 3 , 202 3 Copenhagen, Denmark; Interim Report for the First Six Months Ended June 30, 2023 Highlights EPKINLY™ (epcoritamab- bysp ) was approved by the U.S. Food and Drug Administration (U.S. FDA) as the first bispecific antibody t...